GW Pharma Clinical Trial Data on CBD for Epilepsy and Schizophrenia

GW Pharma Clinical Trial Data on CBD for Epilepsy and Schizophrenia The passage provides detailed results from pharmaceutical studies on CBD but contains no references to high‑profile individuals, government agencies, or controversial financial flows. It is essentially a summary of trial outcomes, offering little investigative value beyond standard drug efficacy reporting. Key insights: Epidiolex (CBD) shows seizure reduction in Lennox‑Gastaut syndrome at 10 mg/kg and 20 mg/kg doses.; Exploratory Phase IIa trial suggests CBD may improve positive symptoms in treatment‑resistant schizophrenia.; Safety profile appears comparable to placebo with mild adverse events.